Tumor Heterogeneity in Breast Cancer
Tumor heterogeneity is the topic de jour, partly because molecular biologists and researchers are identifying it using sophisticated gene/DNA analysis techniques. Clinicians and pathologists are well acquainted with marked variability in clinical presentations, tumor histology, and, more importantly, clinical outcomes of their patients. In this review, we address these issues head-on and document that tumor heterogeneity is an old friend (or, more correctly, a foe). We described heterogeneity that exists at all levels—clinical, histologic, and molecular—and briefly outline the strategies that have been used by clinicians and pathologists to tackle this complicated issue.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Advances in anatomic pathology - 22(2015), 5 vom: 02. Sept., Seite 294-302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Badve, Sunil [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 10.05.2016 Date Revised 12.08.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/PAP.0000000000000074 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251729133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251729133 | ||
| 003 | DE-627 | ||
| 005 | 20231224162630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PAP.0000000000000074 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0839.xml |
| 035 | |a (DE-627)NLM251729133 | ||
| 035 | |a (NLM)26262511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Badve, Sunil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor Heterogeneity in Breast Cancer |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2016 | ||
| 500 | |a Date Revised 12.08.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tumor heterogeneity is the topic de jour, partly because molecular biologists and researchers are identifying it using sophisticated gene/DNA analysis techniques. Clinicians and pathologists are well acquainted with marked variability in clinical presentations, tumor histology, and, more importantly, clinical outcomes of their patients. In this review, we address these issues head-on and document that tumor heterogeneity is an old friend (or, more correctly, a foe). We described heterogeneity that exists at all levels—clinical, histologic, and molecular—and briefly outline the strategies that have been used by clinicians and pathologists to tackle this complicated issue | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Gökmen-Polar, Yesim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in anatomic pathology |d 1997 |g 22(2015), 5 vom: 02. Sept., Seite 294-302 |w (DE-627)NLM093789904 |x 1533-4031 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2015 |g number:5 |g day:02 |g month:09 |g pages:294-302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PAP.0000000000000074 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2015 |e 5 |b 02 |c 09 |h 294-302 | ||